Regulatable IL-15 engineered TIL therapy in ICI-resistant melanoma: RP2D ORR 66.7% (10/15)
Amsokigene autoleucel (OBX-115) expresses acetazolamide-regulatable membrane-bound IL-15, removing the need for exogenous IL-2. In pooled phase 1 and 1/2 data in immune checkpoint inhibitor (ICI)-resistant advanced melanoma, 10 of 15 patients at the recommended phase 2 dose (RP2D) achieved objective responses (66.7%; 95% CI 38–88%), including two complete responses. No dose-limiting toxicities, ICU admissions, or treatment-related deaths occurred.

Background and open questions
Tumor-infiltrating lymphocyte (TIL) therapy has shown clinical activity in advanced melanoma, but current regimens require high-dose exogenous IL-2 to support T-cell expansion and persistence, which causes substantial toxicity including capillary leak syndrome. Whether a pharmacologically controllable cytokine signal built into the cell product could support TIL function without systemic IL-2 remained untested in humans.
Study design
The investigators conducted two single-arm early-phase trials (phase 1 and phase 1/2) in patients with checkpoint-inhibitor-resistant advanced melanoma. Amsokigene autoleucel (OBX-115) is an autologous TIL product engineered to express a membrane-bound form of IL-15 whose activity is switched on by the small-molecule drug acetazolamide. Patients received lymphodepleting chemotherapy followed by TIL infusion without exogenous IL-2. The pooled analysis evaluated 37 treated patients, with 15 at the recommended phase 2 dose (RP2D).
Key results
- At the RP2D (Key Efficacy Set: phase 1 DL3 plus phase 2, 15 patients), 10 achieved objective responses (66.7%; 95% CI 38–88%), including 2 complete responses; in the phase 2 cohort alone (9 patients), ORR was 6/9 (66.7%).
- The first patient experienced rapid lymphocyte expansion and edema around a previously irradiated brain metastasis (not meeting DLT criteria), prompting protocol modifications: maximum cell dose reduced 80%, acetazolamide dose reduced 75%.
- Common grade ≥3 treatment-emergent adverse events (TEAEs) included neutropenia (64.9%), leukopenia (56.8%), and lymphopenia (56.8%), primarily attributable to lymphodepleting chemotherapy.
- No dose-limiting toxicities, ICU admissions, or treatment-related deaths occurred; serious TEAEs occurred in 10/37 patients.
- Median follow-up was 8.3 months; median PFS was 8.1 months.
Mechanistic interpretation
The data provide human proof-of-concept that a membrane-bound cytokine signal under small-molecule control can support TIL expansion and antitumor activity without the systemic toxicity of high-dose IL-2. The acetazolamide-dependent switch offers a potential safety lever if uncontrolled expansion occurs.
Limitations
- The dataset is small and nonrandomized; the pooled analysis (post hoc) does not establish comparative efficacy versus approved TIL products or other melanoma therapies.
- These are early-phase data; durability, long-term safety, and efficacy in larger populations remain to be determined.
- The dose-adjustment history after the first patient's adverse event (which did not meet DLT criteria) underscores that the optimal regimen is still being refined.
Authors and source
Nature Medicine (2026). Published online 3 November 2026. https://doi.org/10.1038/s41591-026-04743-6.
Numbers are as reported by the authors. Corrections: contact@
Related science
Anti-GDF-15 visugromab plus nivolumab before surgery in bladder cancer: pCR 33% vs 8%
In the phase 2a GDFATHER-NEO trial, adding GDF-15 neutralisation to nivolumab raised pathologic responses without adding grade 3–4 toxicity
RELATIVITY-047 at 5 years: relatlimab plus nivolumab, overall survival 48% vs 38%
In first-line advanced melanoma, the PFS, OS and melanoma-specific survival gaps over nivolumab alone widened to about 10 points or more
In vivo BCMA CAR-T phase 1: 15 months of follow-up, one ongoing sCR
Green CAR-T cells attacking a red myeloma cell at right
One email, with links to every paper. Reports and custom landscapes: contact@inlightbio.com.
Opens your email app with a pre-filled request; we add you by hand. Free, unsubscribe any time.


